 |
2 Products |  |
30 Diseases | | 2 Products |
|
4 Trials |  |
91 News |  |
| «12 |
- rasagiline / Generic mfg.
[VIRTUAL] ALZHEIMER’S DRUG DEVELOPMENT PIPELINE: NOVEL TARGETS AND INNOVATIVE APPROACHES (Hall E) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_54;
One novel combination approach consists of losartan, amlodipine, atorvastatin and exercise and rasagiline is an example of molecule with pleiotropic effects on dopamine and disease-biology pathways...Novel designs being integrated into AD drug development include basket trials, randomized withdrawal trials, serial parallel comparison designs, and platform trials. Conclusions Progress in development of agents with novel targets and novel approaches will accelerate drug development for AD, clarify the disease-biology, and contribute to the development of treatments and treatment combinations for different phases of AD.
- | LucaVax (tertomotide) - KAEL / GemVax
Journal, IO Biomarker: GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-κB/VEGF pathway. (Pubmed Central) - Nov 29, 2019
GV1001 was effective in suppressing tumor growth and inducing apoptosis in a CRPC xenograft mouse model. Our data demonstrated that GV1001 inhibited cell viability, induced apoptosis, and inhibited angiogenesis in CRPC cells by inhibition of the AKT/NF-κB/VEGF signaling pathway.
- | LucaVax (tertomotide) - KAEL / GemVax
Preclinical, Journal: The Novel Peptide Vaccine GV1001 Protects Hearing in a Kanamycin-induced Ototoxicity Mouse Model. (Pubmed Central) - Nov 19, 2019
GV1001 itself did not have any detrimental effects on the inner ear or kidney. In the KM induced ototoxicity model, concomitant administration of GV1001 protected against cochlear hair cell damage and preserve hearing.
- LucaVax (tertomotide) - KAEL / GemVax
A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients (Room B) - Oct 29, 2019 - Abstract #ESMOIO2019ESMO_IO_233;
In conclusion, riavex as an anti-cancer vaccine is relatively safe in heavily pre-treated solid cancer patients and is assessed to improve quality of life, although the treatment response is not promising.Legal entity responsible for the study: The author. Funding: Has not received any funding.
- LucaVax (tertomotide) - KAEL / GemVax
MAPT TRIAL: 5-YEAR FOLLOW-UP RESULTS () - Oct 16, 2019 - Abstract #CTAD2019CTAD_36;
P2
Further investigation will be required to con rm these observations in a large-scale and longer-term clinical evaluation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03184467 Registered on 12 June 2017.
- LucaVax (tertomotide) - KAEL / GemVax
A MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN, PROSPECTIVE, PHASE II CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF GV1001, A NOVEL PEPTIDE MIMICKING HUMAN TELOMERASE REVERSE TRANSCRIPTASE, FOR THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER’S DISEASE. () - Oct 16, 2019 - Abstract #CTAD2019CTAD_10;
Most of these reductions were maintained after PVC and thus are not attributable solely to gray matter tissue loss. Further longitudinal studies are needed to characterize the temporal course of synaptic alterations in AD in relation to amyloid and tau deposition, as well as the associations with cognitive and functional change.
- UV1 / Ultimovacs
Long term outcomes of a Phase I Study with UV1, a Second Generation Telomerase Based Vaccine, in Patients with advanced Non-Small Cell Lung Cancer (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_704;
These responses occurred more rapidly and were stronger compared to lower doses and the patients in this group had a 3-year OS of 83%. This, together with the safety and clinical outcome data, favours 700 mg as the preferred UV1 dose in this patient population.
- | LucaVax (tertomotide) / GemVax & KAEL
New P3 trial: Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) (clinicaltrials.gov) - Jul 24, 2019
P3, N=417, Not yet recruiting, Sponsor: GemVax & Kael
- | LucaVax (tertomotide) / GemVax & KAEL
New P2a trial: GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) (clinicaltrials.gov) - May 21, 2019
P2a, N=90, Not yet recruiting, Sponsor: GemVax & Kael
- | Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Trial completion, Metastases: Immunochemoradiotherapy in Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 12, 2018
P1, N=11, Completed, Sponsor: Providence Health & Services
This, together with the safety and clinical outcome data, favours 700 mg as the preferred UV1 dose in this patient population. Active, not recruiting --> Completed
- ||||| LucaVax (tertomotide) / GemVax & KAEL
New P2 trial: Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients (clinicaltrials.gov) - Jun 12, 2017
P2, N=90, Recruiting, Sponsor: GemVax & Kael
- |||| LucaVax (tertomotide) / GemVax & KAEL
Trial completion: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH (clinicaltrials.gov) - Nov 22, 2016
P2, N=161, Completed, Sponsor: GemVax & Kael
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | LucaVax (tertomotide) / GemVax & KAEL
New P2 trial: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH (clinicaltrials.gov) - Aug 4, 2016
P2, N=161, Active, not recruiting, Sponsor: GemVax & Kael
- || LucaVax (tertomotide) / GemVax & KAEL
New P3 trial, Metastases: KG 4/2015: A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients (clinicaltrials.gov) - Aug 3, 2016
P3, N=148, Recruiting, Sponsor: Samsung Pharmaceutical Co., Ltd.
- | Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Trial completion, Metastases: CRUK-TELOVAC-V4: Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Aug 22, 2013
P3, N=1110, Completed, Sponsor: Royal Liverpool University Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, LucaVax (tertomotide) / GemVax & KAEL
Enrollment closed, Metastases: Immunochemoradiotherapy in Patients With Pancreatic Cancer (clinicaltrials.gov) - Jul 12, 2012
P1, N=11, Active, not recruiting, Sponsor: Providence Health & Services
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| LucaVax (tertomotide) / GemVax & KAEL
New P3 trial: Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 12, 2012
P3, N=600, Not yet recruiting, Sponsor: Kael-GemVax Co., Ltd.
- Oncopore (ruxotemitide) / Verrica
Enrollment change, Surgery: A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma (clinicaltrials.gov) - Jan 9, 2012
P1, N=12, Completed, Sponsor: Lytix Biopharma AS
Recruiting --> Active, not recruiting N=20 --> 12
- | Oncopore (ruxotemitide) / Verrica
Trial completion, Surgery: A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma (clinicaltrials.gov) - Jan 9, 2012
P1, N=12, Completed, Sponsor: Lytix Biopharma AS
N=20 --> 12 Recruiting --> Completed